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ABSTRACT: Organic compounds bearing radioisotopes of iodine are widely used
for biological research, diagnostic imaging, and radiotherapy. Early reported synthetic
methods for the incorporation of radioiodine have generally involved high
temperature reactions or strongly oxidizing conditions. To overcome these limitations
and to cope with the demand for novel radioiodinated probes, there has been a surge
in the development of new synthetic methodology for radioiodination. This synopsis
describes the key transformations developed recently.
Organic compounds bearing radioisotopes of iodine play amajor role in nuclear medicine and molecular imag-
ing.1−3 As there are a number of radioactive iodine isotopes
(Table 1), a single biologically or medicinally active iodinated
compound can be labeled with different radioisotopes for a
particular application. For example, compounds bearing
iodine-123 or iodine-124 can be used for the diagnostic
imaging of disease via single photon emission computed
tomography (SPECT) or positron emission tomography
(PET) techniques, respectively.4−6 Radiopharmaceuticals
bearing iodine-131 are used for radiotherapy, while iodine-
125 labeled compounds are commonly used in preclinical,
biological, and medicinal chemistry applications.
The importance of radioiodinated probes and agents in
nuclear medicine and imaging has required the development of
efficient synthetic methods for the preparation of these
compounds.4−6 In a similar manner to conventional synthetic
chemistry, the aim of these methods is to produce radio-
iodinated compounds as efficiently as possible. In radio-
chemistry, this is measured using RadioChemical Yield (RCY,
the amount of activity in the isolated product expressed as a
percentage of starting activity) or RadioChemical Conversion
(RCC, the amount of activity in the nonisolated product,
usually obtained from a radio-HPLC and expressed as a
percentage of starting activity) and RadioChemical Purity
(RCP, the percentage of activity of the radionuclide with
respect to the total activity of all radionuclides in the sample).7
The other important property of radioiodinated compounds is
Molar Activity (Am, the measured radioactivity per mole of
compound, typically expressed as becquerels per micromole).
For imaging applications, radiolabeled compounds with high
molar activity are important to generate actual tracer
conditions, where the biological target is mainly bound with
radioactive compounds and not nonradioactive species. The
level of molar activity required for imaging is highly dependent
on the context and biological target. However, in developing
radioiodination methods, final compounds with molar
activities in the GBq.μmol−1 range of magnitude are
considered suitable. Unlike the radioisotopes commonly used
in PET imaging (e.g., 11C, 18F), the radioisotopes of iodine
have relatively long half-lives and for this reason, synthetic
methods for radioiodination are more varied.4−6,8−11 As
radioiodine isotopes are produced in iodide form,12 early
reported methods have involved nucleophilic substitution
reactions, such as the use of high temperature and solid state
halogen exchange reactions (e.g., Scheme 1).13 Alternatively,
radioactive iodide can be oxidized to iodine or iodine
monochloride and used in electrophilic substitution reactions,
such as the iododestannylation of aryltin compounds.14
Although these methods allow the iodination of various
compounds with high RCY and RCP, the harsh reaction
conditions, challenging purifications (such as the removal of
organotin residues) and the need for more varied and
sometimes complex targets have required the development of
new radioiodination reactions. To meet this demand, a variety
of new transformations for the incorporation of radioiodine
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Table 1. Radioiodine Isotopes Most Commonly Used in
Imaging and Therapy
isotope half life
type of
emissiona application
123I 13.2 h γ SPECT imaging
124I 4.18 days β+ PET imaging
125I 59.4 days Auger e− preclinical research and therapy
131I 8.04 days β− therapy
aγ: gamma ray emission, β+: positron emission, β−: electron emission.
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into organic compounds have been developed in recent years.
This synopsis describes these key synthetic advances and in
particular, the main transformations used for the preparation of
radioiodine bonds with Csp, Csp2, and Csp3 centers.
1. RADIOIODINATION OF CSP
2 CENTERS
1.1. Nucleophilic Aromatic Substitution Reactions.
Isotopic and Halogen Exchanges. Direct replacement of
stable iodine isotopes on organic molecules by a radioiodine
isotope, also called isotopic exchange, is a well-known
procedure. The reaction is usually performed neat, with the
radioiodide ion, at very high temperature and most often in the
presence of sulfate salts and oxidants such as dioxygen from the
air (Scheme 1).13 Isotopic exchange can also be realized in
water at high temperature, but in this case, addition of copper
sulfate as a reagent has been evidenced to both promote the
radioiodination and shorten reaction times (Scheme 2).13,15,16
However, due to the impossible separation of nonradioactive
and radioactive iodinated products, this method is not suitable
to access radioiodinated molecules in the GBq·μmol−1 range of
magnitude.
In order to restore optimal molar activities, bromine−iodine
exchanges can be performed using the same conditions as
isotopic exchanges. Thus, in 2014, Brownell et al. described the
radioiodination of [123I]IPEB, a metabotropic glutamate
receptor subtype 5 radioligand, through bromine−iodine
exchange at high temperature in the presence of copper and
tin sulfate (Scheme 3).17 Solid-state synthesis can also be used.
For example, the radiosynthesis of a Matrix MetalloProteinase-
12 (MMP-12) iodinated probe was described by Mukai in
2018.18 Overall, bromine−iodine exchange appears to give
comparable RCYs as isotopic exchange along with higher
molar activities but in all cases at the cost of very harsh
reaction conditions.
Diazo and Triazene Leaving Groups. In 2017, Sutherland
et al. described an efficient methodology to radioiodinate aryl
amines via stable diazonium salts (Scheme 4).19 This
methodology is based on the use of widely available starting
materials and a polymer supported nitrite reagent, which
allowed both the formation of diazonium salts and the
subsequent Sandmeyer reaction to take place under mild
conditions. The incorporation of the radioiodine atom was
done thereafter using sodium iodide. This one-pot method-
ology was used on eight example substrates, demonstrating its
functional tolerance, as well as generating several SPECT
tracers, including [125I]iomazenil, [125I]CNS1261, and
[125I]IBOX with RCYs between 47 and 75%. Triazene
derivatives can also be used in SNAr reactions; however, even
if these precursors are stable and can be isolated, they are
usually less reactive than the corresponding diazonium
salts.20,21
Iodonium Leaving Groups. In 2016, Gestin et al. published
a systematic study aimed at comparing the reactivity of
aryliodonium salts in radiolabeling using either sodium iodide
or astatide.22 Their investigations showed that the use of
acetonitrile as solvent, at 90 °C, with iodonium sulfonate were
the optimal conditions to perform efficient radioiodination
from iodonium salts. The regioselectivity of the nucleophilic
substitution of unsymmetrical iodoniums salts was found to be
controlled by electronic and steric effects. The same authors
have used this methodology to radiolabel activated esters
acting as prosthetic groups able to bind biomolecules. Thus, N-
[125I]succinimidyl-3-iodobenzoate ([125I]SIB) was obtained in
36−87% RCY, depending on the nature of the electron-rich
Scheme 1. Early Methods of Radioiodination13,14
Scheme 2. General Isotopic Exchange Procedure13,16
Scheme 3. Typical Bromine−Radioiodine Exchange
Procedure17
Scheme 4. Radioiodination of Aryl Amines through
Diazotization by Sutherland19
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arene moiety (Scheme 5).23 In 2019, this methodology was
applied to the radiolabeling of two other prosthetic groups, for
attachment to biomolecules by either click chemistry or
inverse-electron-demand Diels−Alder reactions.11
1.2. Electrophilic Aromatic Substitution Reactions.
Electrophilic aromatic substitution is a very popular strategy to
perform radioiodination, which can be applied either directly
with the compound of interest or using a prefunctionalized
precursor. Nevertheless, this procedure requires the generation
of an electrophilic iodine species, which is typically prepared
from sodium iodide and a strong oxidant such as hydrogen
peroxide, peracids, N-halosuccinimides, or N-chloroamides.
Direct SEAr. Direct electrophilic aromatic substitution is a
typical process to perform radioiodination of aromatic
molecules.24 Generally, this strategy exhibits low regioselectiv-
ity unless there has been careful choice of starting compound.
In these cases, the reaction can lead to the radioiodinated
compound with good RCY and high molar activity. For
example, this approach has been used for the direct and
regioselective radioiodination of the 4-aminobenzoic core
found in numerous 5-HT4 receptor ligands (Scheme 6).
In 2016, a silver-catalyzed radioiodination was reported,
which used the mild Lewis acid nature of a silver triflimide salt,
avoiding the poly iodination of activated aromatic rings
(Scheme 7).25 The completely regioselective radioiodination
of electron-rich substrates (as observed by nonradioactive
reactions) facilitated by this method has enlarged the panel of
substrates accessible to direct SEAr reactions. Nevertheless, to
overcome the regioselectivity issues of other SEAr strategies,
the preparation of stannylated, silylated, or boronated
precursors is generally required to perform ipso SEAr.
Iododestannylation. Iododestannylation is the most used
methodology to perform radioiodination in research facili-
ties.1−5 Starting from a stannane precursor, using an in situ
generated iodinated reagent from NaI and an oxidant, the
transformation proceeds smoothly and selectively to afford, via
an ipso SEAr reaction, the radiolabeled derivatives. Despite
issues concerning their stability and toxicity, aryltrialkylstan-
nanes are generally prepared from the corresponding
halogenated precursor through metalation or palladium-
mediated reactions. The major drawback of this reliable
method, often hampering its use in clinics, is the contam-
ination of the obtained radiotracer with organotin residues.
Nevertheless, radioiododestannylation is currently the main
method of choice to perform radioiodination and many small
molecules used as radiotracers, such as [125I]AGI-5198, have
been prepared accordingly (Scheme 8).26
Several approaches have been described recently to
specifically address the purification issues inherent to
iododestannylation. In 2006, the Valliant group employed
fluorine-rich organostannane to perform radioiododestannyla-
tion in order to discard organotin residues through fluorous
solid-phase extraction (Scheme 9). Thus, labeling with
[125I]NaI in the presence of the oxidant, iodogen allowed the
quick formation of the radiolabeled derivatives with RCYs up
to 85% and RCPs up to 98%.27 This method was used by the
same group to produce [125I]iodoxuridine and [125I]FIAU,
with RCYs of 94 and 88%, respectively, while allowing the
efficient removal of organotin precursors through a simple
filtration technique as evidenced by a UV-HPLC technique.28
A similar approach was proposed by the Gestin group in
2016, using an ionic liquid supported stannylated precursor for
Scheme 5. Radioiodination Using Iodonium Salts as
Precursors by Gestin11,22,23
Scheme 6. Typical Radioiodination through Direct
Electrophilic Aromatic Substitution24
Scheme 7. Silver(I) Triflimide Mediated Electrophilic
Radioiodination25
Scheme 8. Radioiodination of [125I]AGI-5198 Using
Radioiododestannylation26
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radiolabeling (Scheme 10).29 This strategy significantly
facilitated the formation and purification of the product,
using a simple SiO2 filtration to separate radio-iodinated
product and organotin precursor, allowing the isolation of
[125I]SIB with 67% RCY and 100% RCP.
In the challenging field of biomolecules radiolabeling, taking
into account synthetic efficacy, half-lives and/or safety issues,
the introduction of the radionuclide is preferred at the last step
of the radio-synthesis. This late stage diversification is generally
achieved using a prosthetic group strategy in order to reach
selectivity toward the radio-labeling site. Several prosthetic
groups have been radioiodinated using an iododestannylation
approach (Scheme 11). For example, [125I]1,2,4,5-tetra-
zines30,31 and a [125I]benzamide moiety32 have been efficiently
prepared using iododestannylation and then attached to the
target biomolecules using inverse electron demand Diels−
Alder and copper-catalyzed condensation reactions, respec-
tively.
Iododesilylation. Silanes can be used as precursors for the
labeling of molecules of interest. However, compared to
iododestannylation, the obtained RCYs are generally lower due
to the higher stability of the carbon−silicon bond. This
methodology has nevertheless been used to label specific
substrates with success, generally in acidic media, starting from
an activated precursor and an electrophilic source of iodine.
For example, in 1993, [131I]MIBG was labeled in 85−90%
RCY by Zalutsky,33 starting from the corresponding
aryltrimethylsilane in TFA, using trifluoroperacetic acid to
generate [131I]I2 in situ (Scheme 12).
In 2016, Tanaka et al. described a polymer-supported
version of the radioiododesilylation applied to the radio-
iodination of iodometomidate (IMTO), a high affinity ligand
of adrenal steroidogenic enzymes, from a polymethacrylamide-
supported precursor (Scheme 13).34 Solid-phase organic
chemistry enabled reaction products to be purified rapidly
and simply by filtration. In this work, the radioiododesilylation
was performed in TFA and used N-chlorosuccinimide (NCS)
to promote the formation of [125I]NIS in situ. After 1 h at 40
°C, TFA was neutralized with a polymer supported amine, and
the purification step of [123I]IMTO was performed through
elution on a Sep-Pak cartridge, while the unreacted
polymethacrylamide-supported precursor was unable to be
eluted. The radiotracer was obtained in 85% RCY and 94%
RCP.
Iododeboronation. The use of boron derivatives to
promote electrophilic radioiodination is well-known and was
first described using boronic acids (Scheme 14). Initially, the
reaction was used to radiolabel a barbituric acid analogue using
chloramine-T to oxidize [125I]NaI, with a 15% RCY.35
Thereafter, the reaction was performed in aqueous HCl and
substantial improvements of the RCYs were observed for the
formation of an [131I]amphetamine analogue36 and 7-[123I]-
iodocognex obtained, respectively, with 86 and 66% RCYs.37
In 2019, iododeboronation from boronic acids was
reinvestigated by the Sutherland and Watson groups (Scheme
15).38 In this work, the role and positive contribution of a
Lewis base was clearly evidenced. Thus, using NCS as an
oxidant and a catalytic amount of KOAc to promote in situ
formation of a boronate, the radioiodination of a variety of
arenes bearing electron-donating or -withdrawing groups was
achieved with RCYs between 49 and 99%. This was further
employed for the radioiodination of biologically active targets,
such as [125I]5-iodouracil, which was generated with a molar
activity of 0.53 GBq·μmol−1.
Ipso-iododeboronation is also possible starting from
boronate derivatives (Scheme 16). The reaction has been
extensively investigated by Kabalka. Using chloramine-T as an
oxidant and under very mild conditions, iododeboronation of
electron rich-neopentylglycolboronic esters or aryltriolborates
has led to the expected radioiodinated arenes.39,40 A similar
approach has been developed by the same authors using
polymer supported organotrifluoroborates, which allowed
easier purification of the radioiodinated compounds.41 Never-
theless, poor RCYs are obtained when electron-poor arenes are
used in these reactions.
Scheme 9. Radioiododestannylation Using Fluorine-Rich Organostannanes by Valliant27,28
Scheme 10. Radioiododestannylation Using Ionic Liquid
Supported Organostannane by Gestin29
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1.3. Transition-Metal-Mediated Approaches. The
purification issues associated with the common method of
the radio-iododestannylation method have necessitated the
development of other metal mediated processes for the
radioiodination of aryl compounds. The main advantage of
many of these methods is the more facile removement of
“inorganic” metal complexes, compared to organotin residues.
Transition-Metal-Mediated Halogen Exchange. Bromine/
iodine exchanges have been reinvestigated by Sutherland et al.
in 2013 using a nickel(0) mediated approach (Scheme 17).42
The reaction proceeded by oxidative addition of Ni(0) into the
aryl C−Br bond, followed by radioiodide exchange of the
resulting Ni(II)−Br species. Reductive elimination generated
the new C−I* bond and allowed the preparation of various
aryl and heteroaryl iodides with RCYs between 88 and 96%.
The radiolabeling of SPECT tracers [125I]iniparib and 5-
[123I]A85380 were also achieved with RCYs of 46 and 93%,
respectively. In addition, the molar activity of 5-[123I]A85380
was found to be 37 GBq·μmol−1. The products of this method
were analyzed by atomic absorption spectroscopy, demonstrat-
ing the absence of any nickel impurities and highlighting the
advantage of using such an approach over more typical
iododestannylation procedures.
Scheme 11. Radioiodination of Biomolecules Using Prosthetic Groups and Iododestannylation30−32
Scheme 12. Radioiododesilylation by Zalutsky33
Scheme 13. Radioiododesilylation and Polymer-Supported
Radioiododesilylation by Tanaka34
Scheme 14. Electrophilic Iododeboronation from Boronic
Acids35−37
The Journal of Organic Chemistry pubs.acs.org/joc JOCSynopsis
https://dx.doi.org/10.1021/acs.joc.0c00644
J. Org. Chem. XXXX, XXX, XXX−XXX
E
Copper-Mediated Iododeboronation. In 2016, Gouverneur
and co-workers described the first copper(II)-mediated
nucleophilic radioiodination of aryl boronic species following
a Chan−Lam mechanism (Scheme 18).43 Using conditions of
80 °C for 20 min in the presence of 1,10-phenanthroline as
ligand, the reaction was tolerant of a broad scope of arenes
bearing both electron-donating and -withdrawing groups,
affording RCCs between 13 and 94%. The reaction was
applicable to both boronic acids and esters, although the use of
boronic acids led to a slightly lower RCC than with pinacol
boronic esters. This methodology was also applied to the
successful radiolabeling of various SPECT radiotracers with
RCYs between 37 and 88%.
A similar approach was developed by Mach et al. in 2018
using a copper(II) catalyst (Scheme 19).44 This procedure
allowed the efficient radioiodination of a variety of pinacol
boronic esters under milder conditions (MeOH/MeCN 4:1,
23 °C for 10 min). The same mild reaction conditions were
also successfully applied to boronic acids, neopentylglycolbor-
onic esters, potassium trifluoroborate salts, as well as MIDA
derivatives. Using pinacol boronates, this methodology was
applied to the radiolabeling of iodinated olaparib analogues
and for the preparation of [125I]KX1 with RCYs between 61
and 99%.
Concomitantly to the Gouverneur work, Zhang et al.
published an iododeboronation procedure starting from
boronic acids using a copper(I) catalyst, Cu2O (Scheme
20).45 Using iodine-131 as the radioisotope, the reaction
occurred smoothly at room temperature in one hour, achieving
RCCs between 87 and 99%. This procedure was applied to the
radiolabeling of MIBG as well as succinimidyl p-iodobenzoate
(SIB).
Gold-Mediated Iododeboronation. In 2018, Sutherland et
al. described the first homogeneous gold catalysis procedure
for the radio-iododeboronation of aryl boronic acids (Scheme
21).46 The air tolerant method was performed using a gold(I)
complex, an electrophilic source of iodine, generated from
NCS and [125I]NaI, in the eco-friendly solvent dimethyl
carbonate. The transformation allowed the radiolabeling of
Scheme 15. KOAc-Catalyzed Iododeboronation by
Sutherland and Watson38
Scheme 16. Electrophilic Iododeboronation from Boronic
Esters and Boronates by Kabalka39−41
Scheme 17. Nickel-Mediated Halogen Exchange42
Scheme 18. Copper(II)-Mediated Iododeboronation by
Gouverneur43
*Obtained after TFA deprotection of the N-Boc derivative
Scheme 19. Copper(II)-Mediated Iododeboronation by
Mach44
*3,4,7,8-Tetramethyl-1,10-phenanthroline (5 mol %) was added to
the reaction.
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electron donating and electron withdrawing substituted arenes
with RCYs between 92 and 100%. Two radiotracers,
[125I]MIBG and a radioiodinated olaparib analogue were
prepared following this procedure, with RCYs of 28 and 41%,
respectively. The molar activity of [125I]MIBG was up to 2.73
GBq·μmol−1.
Click Chemistry. In 2013, Yan and Årstad proposed a one-
pot radioiodination of 1,2,3-triazoles using copper(I)-mediated
click chemistry (Scheme 22).47 Their protocol promoted the
formation of highly functionalized radioiodinated triazoles
through 1,3-dipolar cycloaddition, generating a vinyl copper
intermediate that underwent iododecupration. In 2018, this
strategy was applied to the synthesis of a multimodal triazole
imaging probe decorated with a fluorophore and incorporating
iodine-124.48
C−H Radioiodination. In 2018, the group of Cailly applied
palladium-mediated C−H activation processes to the field of
radioiodination.49 Their first efforts were focused on the use of
N-acylsulfonamide as a directing group with palladium acetate
to promote the formation of palladacycles (Scheme 23). Thus,
crude palladacycle solutions were prepared and reacted with an
[125I]NIS solution obtained from NCS and [125I]NaI. Radio-
iodination was carried out smoothly at room temperature in 15
min after mixing of the two solutions and afforded RCCs
between 44 and 91%. This strategy was also applied to the
labeling of antitumoral N-acylsulfonamides and radioiodinated
analogues of LY32262, tasisulam, and a Bcl-xL/Mcl-1 inhibitor.
The reaction was then extended to other directing groups such
as anilides and carboxamides derivatives, N-Boc-protected
anilines, urea, pyrrazolyl, carboxylic acids, and nitriles. In 2019,
an improvement of this methodology was reported,50 allowing
reduced amounts of palladium acetate (2 mol %) and PTSA (3
mol %), while maintaining RCCs. This new protocol led to an
improvement in the purity of the crude mixture through
abolition of nonradioactive side reactions, as well as an easier
implementation, with palladacycle formation in several minutes
instead of 24 h.
Scheme 20. Copper(I)-Mediated Iododeboronation by
Zhang45
*Obtained after TFA deprotection of the N-Boc derivative.
Scheme 21. Gold(I)-Mediated Iododeboronation by
Sutherland and Lee46
*Obtained after HCl deprotection of the N-Boc derivative.
Scheme 22. One-Pot Radioiodinated 1,2,3-Triazole Synthesis by Yan and Årstad47
Scheme 23. C−H Radioiodination by Cailly49,50,a
aConditions and directing groups (DG). Conditions A: Pd(OAc)2
1.05 equiv, PTSA 2 equiv, MeOH, 24 h, rt with DG = −NHAc,
−NHCOPh, −NMeCOPh, −NHBoc, −CONH2, −CONMe2
−CON(OMe)Me, −CN, −CH2CN, −N-pyrrolidin-2-one, and
−NHCONH(isoBu). Conditions B: PdCl2 1.05 equiv, MeCN, 24 h,
80 °C with DG = −CO2H, −CH2CO2H, and −N-pyrrazolyl.
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2. RADIOIODINATION OF CSP
3 CENTERS
Radioiodine can be introduced into aliphatic groups using
nucleophilic substitution reactions involving the displacement
of typical leaving groups with radioiodide under Finkelstein
conditions.51 While the lability of the Csp3−I bond has
restricted the widespread use of these types of compounds for
in vivo imaging, probes have been synthesized via Finkelstein-
type reactions for specific applications.51 Early methods
involving direct exchange of nonradioactive iodide with
radioiodide were employed for this type of process. Generally,
isotopic exchange reactions produce radiolabeled compounds
in modest molar activity due to competition between the
radioactive and nonradioactive species.52 Despite this issue,
this approach was used in 2013 for the preparation of 123I-
labeled fatty acids (Scheme 24).52 Reaction of the iodinated
fatty acids in acetone with [123I]iodide gave the corresponding
123I-labeled compound with a RCY higher than 95%.
To overcome molar activity issues and aid separation of
starting materials and products, sulfonate53 or halogenated
precursors are more commonly used.51 Simple halogen
exchange, through reaction of an alkyl bromide with
[123I]iodide, was used to prepare radioiodinated rhenacarbor-
ane complexes as potential drug delivery agents for the central
nervous system.54 Accelerated radioiodination via nucleophilic
substitution of an alkyl chloride by amide group anchimeric
assistance has also been recently studied.55 Biologically active
amines were initially acylated with chloroacetyl chlorides.
Various approaches were then used to study the rates and
mechanism of iodination, with 5-membered and 6-membered
intermediates generated from the corresponding chloroamides
benefiting from amide group anchimeric assistance. Never-
theless, shorter chain acyl chlorides were also rapidly
radioiodinated (Scheme 25).
3. RADIOIODINATION OF CSP CENTERS
Methods for the radioiodination of Csp centers and, in
particular, alkynes are rare. Nonetheless, the relative metabolic
stability of alkynes compared to various aryl groups and the
highly chemoselective reactions that can be achieved with
terminal alkynes have led to the development of radio-
iodination methods for the preparation of iodinated alkynes.
Kabalka and Mereddy showed the efficient radioiodination of
alkynyltrifluoroborates using [123I]iodide under oxidative
conditions.56 Initially, the alkynyltrifluoroborates were pre-
pared by lithiation of terminal alkynes followed by reaction
with trimethylborate and then KHF2 (Scheme 26). Radio-
iodination was achieved by peracetic acid in situ oxidation of
sodium [123I]iodide and subsequent iododeboronation of the
alkynyltrifluoroborates. This gave a range of radioiodinated
alkynes with RCY between 85 and 92%.
Direct radioiodination of terminal alkynes has been achieved
using stoichiometric amounts of copper(II) salts (Scheme
27).57 The method which used bathophenanthrolinedisulfonic
acid (BPDS) to solubilize the copper species was proposed to
involve copper(II) oxidation of sodium [123I]iodide. The
resulting electrophilic iodine species then underwent an
iododehydrogenation of the alkyne via a copper acetylide
intermediate. In a proof of concept study, this allowed
radioiodination of phenylacetylene after 30 min in 16% RCY.
4. CONCLUSION
Radioiodinated compounds are widely used for a range of
applications across various fields of medicinal and biological
sciences. In combination with PET and SPECT technologies,
these compounds are now well established for the noninvasive
in vivo visualization and diagnosis of disease. Despite this
importance, the preparation of these compounds has relied
traditionally on the use of harsh conditions, strong oxidants,
and toxic precursors. However, in the last two decades,
significant progress has been made in developing a wide range
of alternative synthetic methodology for the efficient radio-
iodination of organic compounds, under milder conditions.
The development of these novel transformations and the
radiochemical translation of existing reactions has allowed
rapid and effective radioiodination of a diverse range of
structural analogues, particularly aryl systems, which are
commonly found in radiopharmaceuticals. This methodology
can now be used to facilitate the development of novel
Scheme 24. Aliphatic Radioiodination Using Isotopic
Exchange52
Scheme 25. Radioiodination of a Chloroamide via a
Finkelstein-Type Reaction55
Scheme 26. Radioiodination of Alkynyltrifluoroborates
under Oxidative Conditions56
Scheme 27. Direct Radioiodination of Phenylacetylene
Using Copper(II) Salts57
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radiotracers, leading to new applications in radiotherapy, the
imaging of disease and the drug discovery process. Efforts are
now focused on the application of these novel methods for
clinical production of radioiodinated imaging agents.
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